en
Feedback

Don't get caught by a cheater! Telemetrio finds and tags such channels 👉 If you want to see the tag, subscribe

JAMA (Journal of the American Medical Association)

JAMA (Journal of the American Medical Association)

Open in Telegram

All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot

Show more

📈 Analytical overview of Telegram channel JAMA (Journal of the American Medical Association)

Channel JAMA (Journal of the American Medical Association) (@jamaupdates) in the English language segment is an active participant. Currently, the community unites 16 793 subscribers, ranking 1 488 in the Medicine category and 2 227 in the USA region.

📊 Audience metrics and dynamics

Since its creation on невідомо, the project has demonstrated rapid growth, gathering an audience of 16 793 subscribers.

According to the latest data from 31 October, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 278 over the last 30 days and by 4 over the last 24 hours, overall reach remains high.

  • Verification status: Not verified
  • Engagement rate (ER): The average audience engagement rate is 4.14%. Within the first 24 hours after publication, content typically collects 1.91% reactions from the total number of subscribers.
  • Post reach: On average, each post receives 695 views. Within the first day, a publication typically gains 320 views.
  • Reactions and interaction: The audience actively supports content: the average number of reactions per post is 1.
  • Thematic interests: Content is focused on key topics such as patient, disease, treatment, drug, guideline.

📝 Description and content policy

The author describes the resource as a platform for expressing subjective opinions:
“All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot”

Thanks to the high frequency of updates (latest data received on 01 November, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.

Buy Ad
16 793
Subscribers
+424 hours
+377 days
+27830 days
Attracting Subscribers
Nov '26
November '26
+8
in 0 channels
October '26
+291
in 0 channels
Get PRO
September '26
+301
in 0 channels
Get PRO
August '26
+361
in 0 channels
Get PRO
July '26
+440
in 0 channels
Get PRO
June '26
+422
in 1 channels
Get PRO
May '26
+584
in 0 channels
Get PRO
April '26
+437
in 0 channels
Get PRO
March '26
+217
in 0 channels
Get PRO
February '26
+247
in 0 channels
Get PRO
January '26
+321
in 0 channels
Get PRO
December '25
+277
in 0 channels
Get PRO
November '25
+366
in 2 channels
Get PRO
October '25
+164
in 0 channels
Get PRO
September '25
+12
in 0 channels
Get PRO
August '25
+29
in 0 channels
Get PRO
July '25
+30
in 0 channels
Get PRO
June '25
+17
in 0 channels
Get PRO
May '25
+9
in 0 channels
Get PRO
April '25
+5
in 0 channels
Get PRO
March '25
+17
in 0 channels
Get PRO
February '25
+12
in 0 channels
Get PRO
January '25
+18
in 1 channels
Get PRO
December '24
+237
in 0 channels
Get PRO
November '24
+1 122
in 0 channels
Get PRO
October '24
+1 120
in 0 channels
Get PRO
September '24
+1 527
in 1 channels
Get PRO
August '24
+1 128
in 1 channels
Get PRO
July '24
+1 216
in 0 channels
Get PRO
June '24
+781
in 1 channels
Get PRO
May '24
+797
in 1 channels
Get PRO
April '24
+808
in 1 channels
Get PRO
March '24
+821
in 2 channels
Get PRO
February '24
+753
in 1 channels
Get PRO
January '24
+768
in 0 channels
Get PRO
December '23
+716
in 1 channels
Get PRO
November '23
+96
in 1 channels
Get PRO
October '23
+86
in 0 channels
Get PRO
September '23
+73
in 0 channels
Get PRO
August '23
+90
in 0 channels
Get PRO
July '23
+107
in 0 channels
Get PRO
June '23
+105
in 0 channels
Get PRO
May '23
+169
in 0 channels
Get PRO
April '23
+128
in 0 channels
Get PRO
March '23
+84
in 0 channels
Get PRO
February '23
+75
in 0 channels
Get PRO
January '23
+71
in 0 channels
Get PRO
December '22
+74
in 0 channels
Get PRO
November '22
+149
in 0 channels
Get PRO
October '22
+90
in 0 channels
Get PRO
September '22
+138
in 0 channels
Get PRO
August '22
+77
in 0 channels
Get PRO
July '22
+50
in 0 channels
Get PRO
June '22
+96
in 0 channels
Get PRO
May '22
+75
in 0 channels
Get PRO
April '22
+80
in 0 channels
Get PRO
March '22
+65
in 0 channels
Get PRO
February '22
+26
in 0 channels
Get PRO
January '22
+56
in 0 channels
Get PRO
December '21
+44
in 0 channels
Get PRO
November '21
+39
in 0 channels
Get PRO
October '21
+61
in 0 channels
Get PRO
September '21
+66
in 0 channels
Get PRO
August '21
+65
in 0 channels
Get PRO
July '21
+96
in 0 channels
Get PRO
June '21
+120
in 0 channels
Get PRO
May '21
+130
in 0 channels
Get PRO
April '21
+812
in 0 channels
Date
Subscriber Growth
Mentions
Channels
01 November+8
Channel Posts
Are GLP-1 Drugs Safe in Frailty? https://jamanetwork.com/journals/jama/fullarticle/2856274 This Medical News article discusses an analysis of cardiovascular benefits and safety of semaglutide use in trial participants with frailty, defined by accumulated age-related health deficits.

2
Pennsylvania Tops 1000 Measles Cases https://jamanetwork.com/journals/jama/fullarticle/2856273 This Medical News article discusses ongoing measles outbreaks in Pennsylvania and other US states amid declining vaccine coverage.
453
3
JAMA Editors' Summary Podcast October 30, 2026 https://jamanetwork.com/journals/jama/fullarticle/2856302 Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.
448
4
FDA Approves New Drug to Treat Herpes Simplex Virus Lesions https://jamanetwork.com/journals/jama/fullarticle/2856280 The US Food and Drug Administration (FDA) approved a new treatment for adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus (HSV).
444
5
RNAi Targeting Hepatic AGT to Block RAAS Pathway in Hypertension https://jamanetwork.com/journals/jamacardiology/fullarticle/2856139 Hypertension is the most important modifiable risk factor for cardiovascular diseases, which are the leading causes of morbidity and mortality. It remains a global health concern as diagnosis, treatment, and control rates remain poor, with less than 25% of patients achieving the guideline-recommended systolic blood pressure (BP) target of less than 130 mm Hg. Cardiovascular outcome studies, such as the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and the Systolic Blood Pressure Intervention Trial (SPRINT), have demonstrated the cardiovascular outcome benefits of intensive BP control and have influenced hypertension guidelines globally. Most guidelines recommend a BP target of less than 130 mm Hg, which has also contributed to accentuating poor control rates.
461
6
A Review of Low Back Pain https://jamanetwork.com/journals/jama/fullarticle/2855996 To the Editor I read with great interest the comprehensive narrative Review on low back pain, which provided an excellent overview of the epidemiology, diagnosis, and management of this prevalent condition. However, I believe the evidence for skeletal muscle relaxants in acute nonspecific low back pain was presented in a manner that overstated their clinical value.
545
7
A Review of Low Back Pain https://jamanetwork.com/journals/jama/fullarticle/2855997 To the Editor A recent review synthesized articles on nonspecific low back pain from 2005 to 2026. After reading this article, we believe that the recommendation against routine spinal imaging in patients without alarm symptoms or obvious clinical history warrants additional, more nuanced discussion. The designation of low back pain as “nonspecific” is contingent upon excluding identifiable structural pathology. However, several clinically meaningful diagnoses are not identifiable by history or physical examination and require imaging for accurate characterization and management.
502
8
Massachusetts Marketplace Disenrollment Following Enhanced Subsidy Expiration https://jamanetwork.com/journals/jama/fullarticle/2855998 This study uses administrative enrollment data from the Massachusetts Health Marketplace to analyze patterns of Marketplace disenrollment when enhanced subsidies expired vs end-of-year disenrollment in prior years.
456
9
Wagering on Unfinished Experiments—Prediction Markets and Clinical Trial Integrity https://jamanetwork.com/journals/jama/fullarticle/2855990 This Viewpoint discusses the potential impact on recruitment, retention, measurement, or evidence generation after a prediction market platform announced it would host betting on the outcomes of clinical trials and US Food and Drug Administration regulatory reviews, noting that policy action is needed to ensure that prediction markets do not undermine the public interest.
428
10
Editorials https://jamanetwork.com/journals/jama/fullarticle/2855999
396
11
The Future of Coronary Interventions https://jamanetwork.com/journals/jamacardiology/fullarticle/2855708 This Viewpoint provides a brief glance at the future state of coronary intervention in the years ahead.
510
12
Parental Diabetes and Risk of Cardiovascular Disease in Offspring https://jamanetwork.com/journals/jamacardiology/fullarticle/2855710 To the Editor First, the study by Mo et al classified maternal diabetes into gestational and pregestational diabetes but did not account for pregnancy glycemic control. Poorly controlled vs well-controlled diabetes may lead to substantially different offspring risks, and this distinction is critical for clinical counseling and intervention. In Sweden, prenatal diabetes care is universally accessible and high quality. In regions with limited screening or glycemic management, observed risk ratios could be significantly higher. We suggest replication in diverse global cohorts with varying levels of diabetes management.
521
13
Parental Diabetes and Risk of Cardiovascular Disease in Offspring—Reply https://jamanetwork.com/journals/jamacardiology/fullarticle/2855709 In Reply We thank He and colleagues for their thoughtful comments regarding our study on maternal diabetes and offspring cardiovascular disease (CVD) risk. We appreciate their interest in our work and their valuable perspectives on potential mechanisms and future research directions.
446
14
Massive Aortic Root Air Lock During LVAD Implantation https://jamanetwork.com/journals/jamacardiology/fullarticle/2855711 This case report discusses a massive air lock within the aortic root discovered during separation from cardiopulmonary bypass in a man in his 60s who underwent durable left ventricular assist device implantation.
402
15
Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer—Reply https://jamanetwork.com/journals/jama/fullarticle/2855976 In Reply Dr Freund and colleagues raise 2 interesting points regarding the interpretation of the Hydra study findings. First, they argue that not all VTE events during follow-up can be attributed to missed PE at baseline and, as such, should not be labeled as diagnostic failures.
440
16
Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer https://jamanetwork.com/journals/jama/fullarticle/2855977 To the Editor Dr Akerboom and colleagues reported that, among patients with active cancer and suspected pulmonary embolism (PE), the YEARS algorithm was noninferior to computed tomographic pulmonary angiography (CTPA) alone, with a 3-month diagnostic failure rate of 1.8% vs 5.5%. Although we welcome any strategy that limits CTPA in this population, the interpretation of this comparison, in particular of its control group, deserves scrutiny.
486
17
Diagnosis and Management of Acute Rhinosinusitis in Adults https://jamanetwork.com/journals/jama/fullarticle/2855978 This JAMA Clinical Guidelines Synopsis summarizes the 2025 update of the American Academy of Otolaryngology–Head and Neck Surgery Foundation guideline on diagnosis and management of acute rhinosinusitis in adults.
469
18
Toward Coordinated Systems of Care for TIA—The Role and Scope of EDs https://jamanetwork.com/journals/jamaneurology/fullarticle/2855738 In this issue of JAMA Neurology, Mamer and colleagues present national trends in the emergency department (ED)–based care of transient ischemic attack (TIA) from 2013 to 2021. The authors demonstrate remarkable increases in the rate of advanced imaging in the ED and decreases in the hospitalizations of this population. The marked increase in use of vascular imaging is reassuring to see, as the timely identification of significant atherosclerotic disease—especially carotid stenosis requiring revascularization—is a key step in lowering the risk of early recurrent stroke.
705
19
Error in Byline https://jamanetwork.com/journals/jamaneurology/fullarticle/2855739 The Original Investigation titled “Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial,” published online July 27, 2026, and in the September issue, was corrected to add the study group to the byline and a supplement listing the nonauthor collaborators. This article was corrected online.
593
20
Errors in Text, Table 1, Figures 1 to 3, and Supplements https://jamanetwork.com/journals/jamaneurology/fullarticle/2855740 In the Original Investigation titled “Effect of Electroacupuncture on Postherpetic Neuralgia: A Randomized Clinical Trial,” published online first on May 26, 2026, and in the July 2026 issue, there were errors in the article text, Table 1, Figures 1 and 3, and the caption of Figure 2; the protocol in Supplement 1; and eTables 2, 4, 7, 12, and 14, footnote d of eTable 5, and the captions for eFigures 1 and 2 in the original Supplement 2 (now Supplement 3). The author has provided a letter of explanation. This article was corrected online.
528